Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Join Channel
Consolidated Standalone

Cravatex

₹448 18 | 4.2%

Market Cap ₹116 Cr.

Stock P/E 14.2

P/B 1.2

Current Price ₹448

Book Value ₹ 371.4

Face Value 10

52W High ₹686.5

Dividend Yield 0.33%

52W Low ₹ 285

Edit Ratio

Cravatex Research see more...

Overview Inc. Year: 1951Industry: Trading

Cravatex Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Cravatex Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 157 159 155 162 170 87 84 57 57 38
Other Income 2 2 3 2 3 2 6 2 6 6
Total Income 159 162 158 164 173 89 90 58 63 44
Total Expenditure 157 157 151 166 177 104 87 56 60 42
Operating Profit 2 4 7 -3 -4 -14 3 2 4 2
Interest 3 3 4 4 5 4 1 0 0 0
Depreciation 4 4 4 4 9 3 0 0 1 0
Exceptional Income / Expenses 0 0 0 0 0 105 0 0 0 0
Profit Before Tax -5 -3 -1 -10 -18 85 2 1 3 1
Provision for Tax 1 1 -2 1 2 -1 -2 1 0 1
Profit After Tax -6 -4 1 -11 -19 85 4 0 3 1
Adjustments -0 0 0 -0 0 0 0 0 -0 0
Profit After Adjustments -6 -4 1 -11 -19 85 4 0 3 1
Adjusted Earnings Per Share -23.4 -14.2 3.2 -43 -74.2 330.4 14.8 1.6 12 3

Cravatex Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 220 244 233 255 266 356 718 865 532 594 504 236
Other Income 4 4 3 3 4 4 4 5 14 15 12 20
Total Income 224 248 235 257 270 360 722 870 546 610 516 255
Total Expenditure 208 230 218 249 271 361 694 843 544 598 534 245
Operating Profit 16 18 17 8 -1 -1 28 26 2 12 -17 11
Interest 5 8 10 13 11 5 6 14 15 14 14 1
Depreciation 1 3 4 3 3 6 6 15 17 16 16 1
Exceptional Income / Expenses 1 0 0 0 0 0 0 0 0 0 106 0
Profit Before Tax 10 7 3 -7 -15 -12 17 -2 -30 -19 58 7
Provision for Tax 3 2 1 1 -1 0 6 2 1 1 -1 0
Profit After Tax 7 5 2 -8 -14 -12 11 -5 -31 -20 59 8
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 7 5 2 -8 -14 -12 11 -5 -31 -20 59 8
Adjusted Earnings Per Share 28.9 18.9 9.2 -30.7 -53.7 -47.7 41.3 -18.2 -118.4 -77 228 31.4

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -15% -16% 7% 9%
Operating Profit CAGR -242% NAN% 0% NAN%
PAT CAGR 0% 0% 0% 24%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 50% 18% 11% 4%
ROE Average 277% 92% 60% 17%
ROCE Average 69% 18% 16% 11%

Cravatex Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 39 42 44 36 22 9 20 -1 -28 -50 92
Minority's Interest 0 0 0 0 0 0 -0 71 75 75 0
Borrowings 14 16 13 9 80 83 84 83 84 106 0
Other Non-Current Liabilities 9 9 9 9 8 9 8 45 37 27 2
Total Current Liabilities 82 93 98 120 110 107 188 244 217 205 43
Total Liabilities 143 160 164 175 220 208 299 442 385 365 137
Fixed Assets 31 29 29 28 46 41 41 86 70 55 3
Other Non-Current Assets 5 7 6 5 9 9 11 15 13 15 8
Total Current Assets 108 124 129 142 164 158 247 341 302 295 126
Total Assets 143 160 164 175 220 208 299 442 385 365 137

Cravatex Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 0 0 0 7 57 6 7 39 35 38
Cash Flow from Operating Activities 0 0 0 0 35 -13 -5 32 -4 -8 144
Cash Flow from Investing Activities 0 0 0 0 -24 -4 3 -37 21 14 42
Cash Flow from Financing Activities 0 0 0 0 38 -34 -0 37 -21 -4 -168
Net Cash Inflow / Outflow 0 0 0 0 50 -51 -2 32 -4 3 18
Closing Cash & Cash Equivalent 0 0 0 0 57 6 4 39 35 38 56

Cravatex Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 28.87 18.87 9.23 -30.66 -53.66 -47.74 41.26 -18.24 -118.45 -76.95 228.05
CEPS(Rs) 34.57 30.75 23.68 -18.01 -40.51 -25.55 63.44 39.72 -50.96 -13.62 290.52
DPS(Rs) 3.5 3.5 2 0 0 1 2 3 3 3 1.5
Book NAV/Share(Rs) 149.45 164.23 169.55 138.89 83.09 36.1 76.53 -3.96 -109.44 -192.58 357.42
Core EBITDA Margin(%) 5.42 5.49 6.2 2.27 -1.74 -1.58 3.35 2.46 -2.23 -0.55 -5.93
EBIT Margin(%) 7.11 5.97 5.75 2.04 -1.69 -1.99 3.14 1.33 -2.82 -0.74 14.32
Pre Tax Margin(%) 4.68 2.74 1.43 -2.89 -5.7 -3.4 2.35 -0.28 -5.59 -3.12 11.58
PAT Margin (%) 3.4 2 1.03 -3.11 -5.21 -3.47 1.49 -0.55 -5.76 -3.35 11.7
Cash Profit Margin (%) 4.07 3.26 2.63 -1.83 -3.93 -1.86 2.28 1.19 -2.48 -0.59 14.91
ROA(%) 5.95 3.21 1.47 -4.68 -7.03 -5.76 4.2 -1.27 -7.4 -5.31 23.51
ROE(%) 21.06 12.03 5.53 -19.88 -48.34 -80.11 73.26 -50.28 0 0 276.7
ROCE(%) 21.58 14.99 12.16 4.77 -3.41 -5.24 17.96 7.78 -10.5 -3.59 68.8
Receivable days 86.32 99.87 116.83 105.34 92.45 84.27 64.41 67.43 107.22 84.83 57.77
Inventory Days 53.44 52.24 67.38 75.15 67.17 39.95 30.51 34.9 57.17 55.07 44.71
Payable days 49.05 52.85 66.65 63.82 65.07 68.32 29.81 19.47 32.59 27.99 30.99
PER(x) 10.46 13.83 53.66 0 0 0 6.9 0 0 -4.69 1.4
Price/Book(x) 2.02 1.59 2.92 1.64 4.34 10.61 3.72 -81.81 -2.65 -1.87 0.9
Dividend Yield(%) 1.16 1.34 0.4 0 0 0.26 0.7 0.93 1.03 0.83 0.47
EV/Net Sales(x) 0.54 0.52 0.82 0.48 0.64 0.55 0.26 0.23 0.36 0.37 0.05
EV/Core EBITDA(x) 7.32 7.18 11.11 14.53 -155.28 -146.07 6.54 7.36 79.61 18.55 -1.51
Net Sales Growth(%) -8.72 11.04 -4.62 9.54 4.46 33.71 101.7 20.48 -38.49 11.74 -15.26
EBIT Growth(%) -10.38 -6.71 -8.23 -61.12 -186.58 -57.47 418.05 -48.9 -230.38 70.85 1748.93
PAT Growth(%) -18.85 -34.64 -51.07 -432.15 -74.99 11.02 186.42 -144.22 -549.26 35.03 396.33
EPS Growth(%) -18.85 -34.64 -51.07 -432.15 -74.98 11.02 186.42 -144.21 -549.31 35.03 396.34
Debt/Equity(x) 1.19 1.58 1.52 2 6.27 11.26 5.9 -157.02 -5.47 -3.36 0
Current Ratio(x) 1.32 1.34 1.32 1.18 1.49 1.48 1.32 1.4 1.39 1.43 2.95
Quick Ratio(x) 0.92 0.94 0.82 0.71 1.11 1.14 0.87 1.06 1 0.97 2.27
Interest Cover(x) 2.93 1.85 1.33 0.41 -0.42 -1.41 3.99 0.83 -1.02 -0.31 5.22
Total Debt/Mcap(x) 0.59 1 0.52 1.22 1.44 1.06 1.59 1.92 2.06 1.79 0

Cravatex Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 75 75 75 75 75 75 75 75 75 75
FII 0 0 0 0 0 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 25 25 25 25 25 25 25 25 25 25
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 92%
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Debtor days have increased from 27.99 to 30.99days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Cravatex News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!